In contrast, HER2 3+ carcinomas had a low mutation prevalence and phenotypic profiles related to different gene expression profiles than those of the other groups, secondary to HER2 amplification which activates the different signaling pathways less strongly than activating mutations in the PI3K-AKT pathway. Here, ERBB2 is linked to carcinoma.